Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. covers the period ending June 20, 2024. The Company, a foreign private issuer organized under Ontario, Canada laws, reports on the issuance of additional senior secured convertible notes as part of a multi-tranche financing arrangement entered into following its initial business combination in January 2024.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The primary financial activity disclosed is the issuance of debt instruments:
- Subsequent Second Tranche Notes Issued: On June 14, 2024, the Company issued notes with an aggregate principal amount of $312,500 in exchange for $250,000 in subscription amounts.
- Interest Rate: 8.0% per annum, payable monthly in arrears in cash or common shares.
- Total Financing Context: The overall financing agreement allows for up to $12,500,000 in principal. The First Tranche ($3,125,000 principal) and Initial Second Tranche ($312,500 principal) were previously issued.
Material Changes
The material change reported is the funding of an additional portion of the Second Tranche of the convertible debt financing. Notably, the Investors were not contractually obligated to fund this tranche because the Company was not in compliance with all covenants under the Securities Purchase Agreement. However, the Investors exercised their discretion to provide the additional $250,000.
Outlook, Risks, and Unusual Items
Management Commentary and Terms: The newly issued notes are identical to the Initial Second Tranche Notes but exclude conversion floor and reset dates that have already passed. The conversion price is subject to reset on July 25, 2024, October 25, 2024, and January 25, 2025, based on the lower of the initial price or the average daily VWAP.
Risks and Contingencies:
- Covenant Compliance: The Company acknowledged non-compliance with certain covenants, which removed the investors' obligation to fund the tranche.
- Registration Rights: The Company must file a registration statement for the resale of shares underlying these notes. Failure to file or have the statement declared effective by specific deadlines may trigger penalty provisions.
- Discretionary Funding: Future funding of the Second Tranche remains at the Investors' discretion.
Investor Verification Checklist
- Verify the specific covenants under the Securities Purchase Agreement that the Company failed to meet, as this impacts future funding obligations.
- Confirm the status of the Registration Statement required for the resale of shares underlying the new notes and any potential penalty deadlines.
- Review the full text of the Securities Purchase Agreement (Exhibit 4.1) and the Senior Secured Convertible Note (Exhibit 4.2) for complete terms regarding conversion and interest payment options.
- Assess the Company's liquidity position given the reliance on discretionary investor funding for the remaining tranches.